Apr 2025 – Nov 2025 · 7 mos

Nov 2024 – Mar 2025 · 4 mos · On-site

• Directed bioinformatics and computational biology teams to drive multi-omics strategies to optimize library expansion, accelerate target and hit identification, and elucidate compound MoA to advance drug discovery.
• Program Initiation using Data-Driven Insights: Led the conceptualization and initiation of oncology drug discovery programs through data-driven target assessments and therapeutic hypothesis generation, leveraging real-world patient data insights.
• Novel Therapeutic Identification: Identified novel small-molecule therapeutic agents/modalities for oncology and CNS disorders targets.
• Cross-Functional Strategy: Developed and communicated cross-functional strategies integrating protein structure, omics, and disease biology to optimize compound libraries, resulting in a 5-fold increase in compound screening efforts.

Jan 2022 – Oct 2024 · 2 yrs 9 mos · On-site

• Leveraged innovative genomic assays, multi-omics data integration and strategic partnerships to advance translational insights, driving the preclinical discovery pipelines.
• Precision Oncology & Real-World Data: Directed precision oncology discovery efforts, leveraging real-world patient data to identify actionable insights and inform therapeutic strategies.
• External Collaboration & Knowledge Graph Development: Established collaborations with CRO and external partners to generate a knowledge graph linking molecular targets, phenotypes, and small molecules to drive pre-clinical drug discovery.
• Efficiency & Innovation: Doubled the rate of novel druggable protein identification via multi-omics and compound data integration.

Jun 2016 – Nov 2021 · 5 yrs 5 mos

Sep 2015 – Dec 2021 · 6 yrs 3 mos · Paramus, New Jersey, US

• Played a key role in business development by consistently securing new clients and delivering novel analysis solutions for neuropsychiatric and CNS disorders, directly impacting revenue generation.
• Team Leadership & AI/ML Development: Led and mentored the Data Science Informatics group, developing ML/AI algorithms for drug discovery, including inference of drug indications and its adverse effects.
• Strategic Partnerships & Communication: Drove business expansion by developing client research proposals and managing external partnerships, effectively communicating resulting solutions to executive teams, clients, and partners.

Jul 2010 – Aug 2015 · 5 yrs 1 mo · New York City Metropolitan Area · On-site

• Development of computational and ML methods to advance the identification of disease drivers, prediction of drug mechanism of action (MoA), drug repurposing, and discovery of cancer biomarkers.
• Computational Method Development: Developed computational tools to predict drug MoA and prioritize drug combinations, contributing to high-impact publications (Nature, Cell, Science) and patents.
• Disease drivers and biomarker identification: Identified disease drivers and cancer biomarkers using regulatory network analysis and ML methods.

Jan 2008 – Jun 2010 · 2 yrs 5 mos · New York City Metropolitan Area · On-site

• Developed regulatory inference methods from multi-omics datasets and transcription factor binding site inference methods from ChIP-Seq data.

Jan 2005 – Jan 2005 · 0 mo

Jan 2003 – Jan 2008 · 5 yrs · Naples, Italy

Jan 1997 – Jan 2002 · 5 yrs